Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab (IPH2102) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with acute myelogenous leukemia.

Neither of two dose levels of lirilumab, given as maintenance treatment, significantly improved leukemia-free survival vs. placebo. Innate said both doses of the human mAb against killer cell immunoglobulin-like receptors (KIR) also missed the trial’s other efficacy endpoints...